A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Explore the Safety, Tolerability, Pharmacokinetics, and Efficacy of PRAX-114 in the Treatment of Adults With Essential Tremor
Latest Information Update: 02 Dec 2022
At a glance
- Drugs PRAX-114 (Primary)
- Indications Essential tremor
- Focus Adverse reactions
- Sponsors Praxis Precision Medicines
Most Recent Events
- 20 Jul 2022 Status changed from recruiting to withdrawn prior to enrolment since sponsor no longer pursuing indication.
- 09 May 2022 Status changed from planning to recruiting, According to a Praxis Precision Medicines media release.
- 28 Feb 2022 According to a Praxis Precision Medicines media release, the company expects to initiate this study in the first quarter of 2022.